Solventum (NYSE:SOLV) Stock Rating Lowered by Wall Street Zen

Solventum (NYSE:SOLV) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Sunday.

Other research analysts also recently issued reports about the company. Zacks Research downgraded Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. KeyCorp raised their target price on Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a research note on Friday, February 27th. Piper Sandler reissued an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Finally, UBS Group reiterated a “neutral” rating on shares of Solventum in a research report on Friday, November 21st. Seven analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $93.70.

Solventum Stock Performance

Shares of NYSE SOLV opened at $69.30 on Friday. The company has a quick ratio of 0.89, a current ratio of 1.23 and a debt-to-equity ratio of 1.00. The firm’s 50-day moving average price is $77.62 and its two-hundred day moving average price is $76.18. Solventum has a 52-week low of $60.70 and a 52-week high of $88.20. The stock has a market capitalization of $12.02 billion, a P/E ratio of 7.81, a P/E/G ratio of 1.14 and a beta of 0.40.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, February 26th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $1.50 by $0.07. The company had revenue of $2 billion during the quarter, compared to analyst estimates of $1.96 billion. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The business’s revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.41 earnings per share. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, sell-side analysts forecast that Solventum will post 6.58 earnings per share for the current year.

Solventum announced that its Board of Directors has authorized a stock repurchase plan on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 7.5% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Hilltop National Bank increased its holdings in shares of Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares during the period. CrossGen Wealth LLC bought a new position in Solventum in the 4th quarter valued at about $25,000. Measured Wealth Private Client Group LLC bought a new position in Solventum in the 3rd quarter valued at about $25,000. Deseret Mutual Benefit Administrators increased its stake in Solventum by 78.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after buying an additional 163 shares during the period. Finally, JNBA Financial Advisors increased its stake in Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after buying an additional 228 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.